Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743

April 28, 2026 | Comments Off on Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743

Journal of Clinical Oncology 2026 March 20 [Link] Arnaud Scherpereel, Paul Baas, Anna K Nowak, Anne S Tsao, Nobukazu Fujimoto, Solange Peters, Aaron S Mansfield, Sanjay Popat, Yolanda Bautista Aragon,…

Mesothelioma location influences the tumour microenvironment and immune checkpoint therapy response in preclinical models

April 27, 2026 | Comments Off on Mesothelioma location influences the tumour microenvironment and immune checkpoint therapy response in preclinical models

Scientific Reports 2026 February 25 [Link] M Lizeth Orozco Morales, Sally M Lansley, Wee Loong Chin, Caitlin M Tilsed, Nicola Principe, Connull Leslie, Breana J Vitali, Francois X Rwandamuriye, Emma…

Mesothelioma location influences the tumour microenvironment and immune checkpoint therapy response in preclinical models

April 24, 2026 | Comments Off on Mesothelioma location influences the tumour microenvironment and immune checkpoint therapy response in preclinical models

Scientific Reports 2026 February 25 [Link] M Lizeth Orozco Morales, Sally M Lansley, Wee Loong Chin, Caitlin M Tilsed, Nicola Principe, Connull Leslie, Breana J Vitali, Francois X Rwandamuriye, Emma…

Strategic selection of MDM2 inhibitors enhances the efficacy of FAK inhibition in mesothelioma based on TP53 genotype

April 23, 2026 | Comments Off on Strategic selection of MDM2 inhibitors enhances the efficacy of FAK inhibition in mesothelioma based on TP53 genotype

PLoS One 2026 February 23 [Link] Xuerao Ning, Thảo Thi Thanh Nguyễn, Takao Morinaga, Yuji Tada, Hideaki Shimada, Kenzo Hiroshima, Naoto Yamaguchi, Masatoshi Tagawa Abstract Mesothelioma has characteristic genetic changes…

Moving Beyond Morphology: Toward a Morpho-Molecular Classification of Pleural Mesothelioma

April 22, 2026 | Comments Off on Moving Beyond Morphology: Toward a Morpho-Molecular Classification of Pleural Mesothelioma

Journal of Thoracic Oncology 2026 February 20 [Link] Gabrielle Drevet, Lipika Kalson, Laurane Mangé, Francoise Galateau-Salle, Arnaud Scherpereel, Lara Chalabreysse, Julien Mazières, Luka Brcic, Nicolas Alcala, Jean-Michel Maury, Lynnette Fernandez-Cuesta,…

Pleural Fluid Cytology-Histology Correlation in Patients With Malignant Pleural Mesothelioma: A Series of 26 Cases

April 21, 2026 | Comments Off on Pleural Fluid Cytology-Histology Correlation in Patients With Malignant Pleural Mesothelioma: A Series of 26 Cases

Cytopathology 2026 February 20 [Link] John Findley, Matthew Demetrious, Lucas Yan, Lei Yan Abstract Background: To understand the efficacy of pleural effusion cytology in the diagnosis of malignant mesothelioma, we…

A proteomics approach to identify predictive blood biomarkers for pleural mesothelioma in prospective cohorts

April 20, 2026 | Comments Off on A proteomics approach to identify predictive blood biomarkers for pleural mesothelioma in prospective cohorts

Clinical and Experimental Medicine 2026 February 20 [Link] Elton Jalis Herman, Alessandra Allione, Clara Viberti, Marcello Manfredi 2, Alessia Russo, Khadija Sana-Hafeez, Nina Kaiser, Georg Johnen, Thomas Brüning, Dario Mirabelli,…

Present and future of cytoreductive surgery and hyperthermic intrathoracic chemotherapy for pleural metastases: a narrative review

April 17, 2026 | Comments Off on Present and future of cytoreductive surgery and hyperthermic intrathoracic chemotherapy for pleural metastases: a narrative review

European Respiratory Review 2026 February 18 [Link] Amro Hajja, Miral Atout, Rasoul Turko, Haadi Syed, Paula Duarte D’Ambrosio, Ricardo Mingarini Terra, Amal Abdulhaq, Marco Nardini, Marcello Carlo Ambrogi, Marco Lucchi,…

Analysis on the efficacy and safety of chemotherapy combined with or without bevacizumab after CRS+HIPEC in patients with malignant peritoneal mesothelioma: a single-center retrospective study

April 16, 2026 | Comments Off on Analysis on the efficacy and safety of chemotherapy combined with or without bevacizumab after CRS+HIPEC in patients with malignant peritoneal mesothelioma: a single-center retrospective study

Frontiers in Oncology 2026 February 3 [Link] Zhi-Ran Yang, Xin-Li Liang, Xin-Bao Li, Xin-Jing Zhang, He-Liang Wu, Yan-Dong Su, Yan Li, Song-Lin An Abstract Objective: To investigate the efficacy and…

Optimising response to immunotherapies in pleural mesothelioma: clinical data and alternative models for the evaluation of new strategies

April 15, 2026 | Comments Off on Optimising response to immunotherapies in pleural mesothelioma: clinical data and alternative models for the evaluation of new strategies

Thorax 2026 February 17 [Link] Christophe Blanquart, Arnaud Scherpereel Abstract Background: Pleural mesothelioma (PM) is a rare tumour, usually associated with previous asbestos exposure. Standard frontline, pemetrexed/platinum-based chemotherapy has been…

Categories